You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection
SBC: MetalloPharm Topic: NIAAADESCRIPTION (provided by applicant): HCV is responsible for 60% of the cases of chronic hepatitis and 50% of cases of cirrhosis, end- stage liver disease, and liver cancer. An effective vaccine has proved elusive and the preferred therapy with pegylated interferon is effective in less than 50% of patients with genotype 1 and 75% of patients with genotypes 2 or 3. Clearly, new treatment alternative ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
ETSense: Adaptive Portable Essential Tremor Monitor
SBC: Great Lakes Neurotechnologies Inc. Topic: NIADESCRIPTION (provided by applicant): The objective is to design, implement, and clinically assess ETSense , an adaptive, compact, portable essential tremor (ET) monitor for optimizing therapeutic interventions. ET is characterized primarily by postural and kinetic (action) tremors of the limbs, which are rated by various subjective tremor rating scales. These scales all provide a discrete, subjec ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Disease Modifying Biologics for Rheumatoid Arthritis
SBC: Novelmed Therapeutics Inc Topic: NIADESCRIPTION (provided by applicant): Nearly 70 million people in the US suffer from arthritis related conditions[1, 2]. Of these, rheumatoid arthritis (RA) cases constitute approximately 3 million. RA is a chronic systemic inflammatory disease that primarily results in erosive destruction of articular joints with additional variable extra-articular effects. The growing elderly population coupl ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Phage-mediated bioluminescent detection of Yersinia pestis
SBC: GUILD ASSOCIATES INC Topic: NIAIDDESCRIPTION (provided by applicant): Yersinia pestis is designated by the Centers for Disease Control (CDC) and NIAID as a Category A bacterial pathogen. Y. pestis is the etiological agent of the plague (Black Death), a transmissible disease that has beenresponsible for millions of deaths throughout the course of history. Although the natural occurrence of this disease is now relatively rare, the ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Natural product-derived differentiation agents for AML
SBC: INVENIO THERAPEUTICS INC Topic: NCIDESCRIPTION (provided by applicant): Though AML is one of the most common forms of leukemia in adults; the 5 year survival is less than 20-50% in adults and significantly lowers in the elderly. The remarkable success in treating one relatively uncommon subset of AML, acute promyelocytic leukemia (APL), with all trans- retinoic acid (ATRA) illustrates the great promise for differentiation therapy. ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
MRI Image Guided Radiation Therapy (IGRT) system with low cost, highly stable mag
SBC: HYPER TECH RESEARCH INC Topic: NCIDESCRIPTION (provided by applicant): Progress toward full development of ViewRay's Renaissance System 1000 MRI image guided radiation therapy (IGRT) system is being threatened by the growing shortage of helium worldwide. This pioneering technology is aimed at treating cancerous tumors in the abdomen where bodily functions cause significant organ displacements making precise dose delivery dif ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Phase II. Digital Interactive Scene Program for Language in Autism (DISPL-A)
SBC: MONARCH TEACHING TECHNOLOGY, INC. Topic: NIDCDDESCRIPTION (provided by applicant): Autism Spectrum Disorder (ASD) affects 1 in 110 children in the United States. The Centers for Disease Control (CDC) estimates that there are currently 730,000 children in the U.S. between 0 and 21 with ASD. Language impairment is a common characteristic of ASD, commonly affecting the acquisition of more abstract language components (i.e. prepositions, adjectiv ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Phase 2 Selective DAT inhibitor for treatment of Obesity.
SBC: P2D, INC Topic: NIDDKDESCRIPTION (provided by applicant): PD2007 is a selective DAT inhibitor that P2D Bioscience (P2D) is developing for the treatment of obesity. PD2007 is an analog of benztropine (Cogentin) a non-Scheduled, safe FDA-approved drug in clinical use for over 40years. Structure-activity-relationship studies were conducted to improve PD2007 efficacy while decreasing side-effects. Our SBIR Phase 1 data de ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Measurement and classification of vertical and shear forces and distributions in
SBC: BERTEC CORP Topic: NIDDKDESCRIPTION (provided by applicant): Foot ulcers are a prevalent complication in the diabetic population, and despite that, the exact causation of plantar ulcers is still unknown. Research suggests that vertical pressure and horizontal shear play an integral role, but the pressure and shear distributions must be precisely measured on the entire plantar surface. Unfortunately, only pressure distrib ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Controlling Inflammation Due to Cardiac Devices
SBC: Novelmed Therapeutics Inc Topic: NHLBIDESCRIPTION (provided by applicant): NovelMed's lead drug candidate prevents biomaterials induced cellular activation. Activated cells release inflammatory mediators that are responsible for pathological trauma that leads to cardiac, lung, liver, and braininjuries during surgical procedures that require cardiac devices. Our findings provide convincing support for developing YalcixiMab as a tr ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health